Saad Usmani, MD, discusses iberdemide approval in relapsed multiple myeloma

Dr. Saad Usmani, chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the FDA approval of iberdomide plus dexamethasone in relapsed multiple myeloma. The FDA approval was announced in August 2026 and based on findings from the SUCCESSOR-2 trial.